Healthcare systems are complex and highly varied from one country to the next. With significant advances in technologies these systems need to be able to adapt and evolve in order to continually deliver the best care to patients. It is therefore fitting that the focus of the 2018 European ISPOR Congress will be on ‘New Perspectives for Improving 21st Century Health Systems’ and will reflect on the revolutionary transformations that have affected today’s healthcare systems across Europe.
In a continuing vein, the Congress will host forums, workshops and plenary sessions to discuss and evaluate recent developments in health technology assessments, policies and clinical decision making and will address fair and sustainable pricing issues.
The OPEN Access Consulting team, alongside their sister companies pH Associates and Harvey Walsh are exhibiting at stand number 715 under the OPEN Health umbrella. If you are attending we’d love to see you, so pop by the stand or get in touch with Cathy Wright, Managing Director, today to organise a meeting (email@example.com).
12–14th November 2018, Stand 715
This year OPEN Access Consulting are not only exhibiting at stand 715, but together with our sister companies pH Associates and Harvey Walsh will be presenting 12 posters covering research on current topics in market access, patient centred outcomes and real world evidence.
Monday 12th November
Poster Session I (08:45–13:45)
- PCP65: Key considerations for the collection of patient reported outcome (pro) data in real world (RW) studies
- PSY204: Early engagement of the “patient voice” to inform patient reported outcome (pro) measurement in global pivotal treatment trial of cholangiocarcinoma (CCA)
- PSS44: An evaluation of the current treatment pathways and associated NHS resource use for the management of uncontrolled moderate-to-severe atopic dermatitis in secondary care
Poster Session II (15:45–19:15)
- PND105: Multiple sclerosis: The map of patient access to disease modifying treatments in Europe
- PMH63: Access to anti-depressant therapies in England: Is there a postcode lottery?
- PMH56: Access to dementia treatments in England; is this really a priority area for primary care?
- PMD68: A cost-consequence analysis of anaconda versus propofol and midazolam in the long-term sedation of critically-ill surgical patients from the UK NHS perspective
Tuesday 13th November
Poster Session III (08:45–13:30)
- PHP193: The use of MedTech innovation briefings (MIBS) to encourage implementation of innovative technologies
Poster Session IV (15:30–19:00)
- PRM53: The use of proxy markers to define disease stage in patients with malignant melanoma: An observational study using the hospital episode statistics (HES) database in England
- PCV124: Hospital admissions for heart failure in England; an increasing burden on NHS resources and the focus of effective cost containment
Wednesday 14th November
Poster Session V (08:45–13:15)
- PCN232: Variation in access to PD-1 immunotherapies in Europe
- PCN365: An assessment of patient reported outcome (pro) clinical trial data reporting, specific to cholangiocarcinoma (CCA)